Dorothy is a Managing Director of Prospect Venture Partners. Prior to joining Prospect, she was Senior Vice President, Project and Vaccine Integration, Merck Research Laboratories, Merck & Company, Inc.

Dorothy became head of MRL Project Planning & Management in 1992. For the next nine years, she oversaw the integration of R&D project development activities, for both vaccines and small molecules, across the Laboratories. In addition to this responsibility, beginning in 1996, she worked intensively with the Vaccine R&D groups to integrate vaccine development activities. From 1999 to 2001 she was also head of MRL Vaccine Development.

Dorothy joined Merck in 1987 as an Assistant Director in Clinical Pharmacology. During these early years, she was responsible for the clinical development of leukotriene antagonists — studies that provided the clinical proof of concept for the subsequent development of Singulair. For this work she received an MRL Divisional Scientific Award in 1998. In addition, she led the team that designed & implemented the advanced AIDS program during the development of Crixivan, one of the first HIV protease inhibitors that revolutionized the treatment of HIV infection.

Prior to joining Merck, Dorothy received an M.D. from Hopkins University where she was elected to Alpha Omega Alpha and has a B.S. from Harvard University where she graduated summa cum laude. She is board certified in Internal Medicine and Pulmonary Medicine and is an author of many scientific publications and two patents. In addition to her work with Prospect Venture Partners, Dorothy is currently a lecturer in the Department of Physiology and Biophysics, Mount Sinai School of Medicine; founder of Synergee LLC, a private biotechnology consulting firm; and a member of the Defense Science Board Smallpox Vaccine Task Force.